Targeting Leukaemias with Anti-CD7 Antibody & ADC

Time: 12:30 pm


  • Assessing how T cell leukaemias, some acute myeloid and relapsed, refractory leukaemias express CD7 antigen on their surface
  • Discussing how a novel antibody-drug conjugate kills CD7 expressing leukaemias suggesting a target and linker combination for treatment of CD7-expressing cancers
  • Understanding how CD7 bound by antibody is rapidly processed into cells and internalization could also be exploited to introduce other druglike molecules into cancer cells in vivo